Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: A systematic literature review.

Ackroyd SA, Goetsch L, Brown J, Houck K, Wang C, Hernandez E.

Gynecol Oncol Rep. 2019 Mar 27;28:109-115. doi: 10.1016/j.gore.2019.03.012. eCollection 2019 May. Review.

2.

Strategies and challenges for the next generation of antibody-drug conjugates.

Beck A, Goetsch L, Dumontet C, Corvaïa N.

Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17. Review.

PMID:
28303026
3.

A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.

Broussas M, Boute N, Akla B, Berger S, Beau-Larvor C, Champion T, Robert A, Beck A, Haeuw JF, Goetsch L, Bailly C, Dumontet C, Matthes T, Corvaia N, Klinguer-Hamour C.

Mol Cancer Ther. 2016 Aug;15(8):1890-9. doi: 10.1158/1535-7163.MCT-16-0041. Epub 2016 Jun 13.

4.

A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.

Gonzalez A, Broussas M, Beau-Larvor C, Haeuw JF, Boute N, Robert A, Champion T, Beck A, Bailly C, Corvaïa N, Goetsch L.

Int J Cancer. 2016 Oct 15;139(8):1851-63. doi: 10.1002/ijc.30174. Epub 2016 Jul 4.

5.

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB.

BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z.

6.

Evaluation of complement-dependent cytotoxicity using ATP measurement and C1q/C4b binding.

Broyer L, Goetsch L, Broussas M.

Methods Mol Biol. 2013;988:319-29. doi: 10.1007/978-1-62703-327-5_20.

PMID:
23475729
7.

Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement.

Broussas M, Broyer L, Goetsch L.

Methods Mol Biol. 2013;988:305-17. doi: 10.1007/978-1-62703-327-5_19.

PMID:
23475728
8.

Insulin-like growth factor receptor type I as a target for cancer therapy.

Corvaia N, Beck A, Caussanel V, Goetsch L.

Front Biosci (Schol Ed). 2013 Jan 1;5:439-50. Review.

PMID:
23277061
9.

Biological significance and targeting of c-Met tyrosine kinase receptor in cancer.

Goetsch L, Caussanel V, Corvaia N.

Front Biosci (Landmark Ed). 2013 Jan 1;18:454-73. Review.

PMID:
23276936
10.

A novel role for junctional adhesion molecule-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody.

Goetsch L, Haeuw JF, Beau-Larvor C, Gonzalez A, Zanna L, Malissard M, Lepecquet AM, Robert A, Bailly C, Broussas M, Corvaia N.

Int J Cancer. 2013 Mar 15;132(6):1463-74. doi: 10.1002/ijc.27772. Epub 2012 Dec 13.

11.

7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.

Pauwels PJ, Dumontet C, Reichert JM, Beck A, Goetsch L, Corvaia N, Klein C, Coiffier B, Teicher B.

MAbs. 2012 Jul-Aug;4(4):434-44. doi: 10.4161/mabs.20869. Epub 2012 Jul 1.

12.

Tetraspanin CD151 as a target for antibody-based cancer immunotherapy.

Haeuw JF, Goetsch L, Bailly C, Corvaia N.

Biochem Soc Trans. 2011 Apr;39(2):553-8. doi: 10.1042/BST0390553. Review.

PMID:
21428938
13.

The next generation of antibody-drug conjugates comes of age.

Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N.

Discov Med. 2010 Oct;10(53):329-39. Review.

14.

Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.

Goetsch L, Caussanel V.

Biomark Med. 2010 Feb;4(1):149-70. Review.

PMID:
20387311
15.

[The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET].

Bodmer A, Goetsch L, Favet L, Bailly C, Corvaia N, Dietrich PY.

Med Sci (Paris). 2009 Dec;25(12):1090-8. doi: 10.1051/medsci/200925121090. Review. French.

16.

Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.

Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N.

Invest New Drugs. 2011 Feb;29(1):9-21. doi: 10.1007/s10637-009-9328-3. Epub 2009 Sep 24.

PMID:
19777159
17.

Insulin-like growth factor receptor type I as a target for cancer therapy.

Goetsch L, Corvaïa N.

Immunotherapy. 2009 Mar;1(2):265-79. doi: 10.2217/1750743X.1.2.265. Review.

PMID:
20635945
18.

Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.

Broussas M, Dupont J, Gonzalez A, Blaecke A, Fournier M, Corvaïa N, Goetsch L.

Int J Cancer. 2009 May 15;124(10):2281-93. doi: 10.1002/ijc.24186.

19.

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.

Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, Goetsch L, Wurch T, Van Dorsselaer A, Corvaïa N.

Curr Pharm Biotechnol. 2008 Dec;9(6):482-501. Review.

PMID:
19075687
20.

Peptides as tools and drugs for immunotherapies.

Beck A, Klinguer-Hamour C, Bussat MC, Champion T, Haeuw JF, Goetsch L, Wurch T, Sugawara M, Milon A, Van Dorsselaer A, Nguyen T, Corvaïa N.

J Pept Sci. 2007 Sep;13(9):588-602. Review.

PMID:
17602441
21.
22.

Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells.

Beck A, Bussat MC, Zorn N, Robillard V, Klinguer-Hamour C, Chenu S, Goetsch L, Corvaïa N, Van Dorsselaer A, Haeuw JF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):203-18.

PMID:
15833284
24.

Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs.

Jeannin P, Magistrelli G, Herbault N, Goetsch L, Godefroy S, Charbonnier P, Gonzalez A, Delneste Y.

Eur J Immunol. 2003 Feb;33(2):326-33.

25.

Identification of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148.

Goetsch L, Haeuw JF, Champion T, Lacheny C, N'Guyen T, Beck A, Corvaia N.

Clin Diagn Lab Immunol. 2003 Jan;10(1):125-32.

26.

Passive transfer of serum antibodies induced by BBG2Na, a subunit vaccine, in the elderly protects SCID mouse lungs against respiratory syncytial virus challenge.

Plotnicky-Gilquin H, Cyblat-Chanal D, Goetsch L, Lacheny C, Libon C, Champion T, Beck A, Pasche H, Nguyen TN, Bonnefoy JY, Bouveret-le-Cam N, Corvaïa N.

Virology. 2002 Nov 10;303(1):130-7.

27.

Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies.

Jeannin P, Magistrelli G, Goetsch L, Haeuw JF, Thieblemont N, Bonnefoy JY, Delneste Y.

Vaccine. 2002 Dec 19;20 Suppl 4:A23-7. Review.

PMID:
12477424
28.
29.

Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation.

Delneste Y, Magistrelli G, Gauchat J, Haeuw J, Aubry J, Nakamura K, Kawakami-Honda N, Goetsch L, Sawamura T, Bonnefoy J, Jeannin P.

Immunity. 2002 Sep;17(3):353-62.

30.

Stability and CTL-activity of P40/ELA melanoma vaccine candidate.

Beck A, Goetsch L, Champion T, Bussat MC, Aubry JP, Klinguer-Hamour C, Haeuw JF, Bonnefoy JY, Corvaïa N.

Biologicals. 2001 Sep-Dec;29(3-4):293-8.

PMID:
11851331
31.

Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Goetsch L, Gonzalez A, Plotnicky-Gilquin H, Haeuw JF, Aubry JP, Beck A, Bonnefoy JY, Corvaïa N.

Infect Immun. 2001 Oct;69(10):6434-44.

32.

Stability and CTL activity of N-terminal glutamic acid containing peptides.

Beck A, Bussat MC, Klinguer-Hamour C, Goetsch L, Aubry JP, Champion T, Julien E, Haeuw JF, Bonnefoy JY, Corvaia N.

J Pept Res. 2001 Jun;57(6):528-38.

PMID:
11437956
33.

BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice.

Goetsch L, Plotnicky-Gilquin H, Aubry JP, De-Lys P, Haeuw JF, Bonnefoy JY, Nguyen NT, Corvaïa N, Velin D.

Vaccine. 2001 Jul 16;19(28-29):4036-42.

PMID:
11427280
34.

OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway.

Jeannin P, Renno T, Goetsch L, Miconnet I, Aubry JP, Delneste Y, Herbault N, Baussant T, Magistrelli G, Soulas C, Romero P, Cerottini JC, Bonnefoy JY.

Nat Immunol. 2000 Dec;1(6):502-9.

PMID:
11101872
35.

Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein.

Power UF, Plotnicky-Gilquin H, Goetsch L, Champion T, Beck A, Haeuw JF, Nguyen TN, Bonnefoy JY, Corvaïa N.

Vaccine. 2001 Mar 21;19(17-19):2345-51.

PMID:
11257359
36.

Physico-chemical characterization and immunogenicity studies of peptide and polysaccharide conjugate vaccines based on a promising new carrier protein, the recombinant Klebsiella pneumoniae OmpA.

Haeuw JF, Libon C, Zanna L, Goetsch L, Champion T, Nguyen TN, Bonnefoy JY, Corvaia N, Beck A.

Dev Biol (Basel). 2000;103:245-50. No abstract available.

PMID:
11214244
37.

Soluble CD86 is a costimulatory molecule for human T lymphocytes.

Jeannin P, Magistrelli G, Aubry JP, Caron G, Gauchat JF, Renno T, Herbault N, Goetsch L, Blaecke A, Dietrich PY, Bonnefoy JY, Delneste Y.

Immunity. 2000 Sep;13(3):303-12.

38.

Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.

Goetsch L, Plotnicky-Gilquin H, Champion T, Beck A, Corvaïa N, Stâhl S, Bonnefoy JY, Nguyen TN, Power UF.

Vaccine. 2000 Jun 1;18(24):2735-42.

PMID:
10781861
39.

Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae.

Rauly I, Goetsch L, Haeuw JF, Tardieux C, Baussant T, Bonnefoy JY, Corvaia N.

Infect Immun. 1999 Nov;67(11):5547-51.

40.

Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Plotnicky-Gilquin H, Goetsch L, Huss T, Champion T, Beck A, Haeuw JF, Nguyen TN, Bonnefoy JY, Corvaïa N, Power UF.

J Virol. 1999 Jul;73(7):5637-45.

41.

An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein.

Hansson M, Ringdahl J, Robert A, Power U, Goetsch L, Nguyen TN, Uhlén M, Ståhl S, Nygren PA.

Immunotechnology. 1999 Mar;4(3-4):237-52.

PMID:
10231093
42.

Regulation of meiotic S phase by Ime2 and a Clb5,6-associated kinase in Saccharomyces cerevisiae.

Dirick L, Goetsch L, Ammerer G, Byers B.

Science. 1998 Sep 18;281(5384):1854-7.

43.

Flow cytometric quantification of surface-displayed recombinant receptors on staphylococci.

Andréoni C, Goetsch L, Libon C, Samuelson P, Nguyen TN, Robert A, Uhlén M, Binz H, Ståhl S.

Biotechniques. 1997 Oct;23(4):696-702, 704.

PMID:
9343695
44.

Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S-phase transition and identifies a conserved family of proteins.

Mathias N, Johnson SL, Winey M, Adams AE, Goetsch L, Pringle JR, Byers B, Goebl MG.

Mol Cell Biol. 1996 Dec;16(12):6634-43.

45.

Role of calmodulin and Spc110p interaction in the proper assembly of spindle pole body compenents.

Sundberg HA, Goetsch L, Byers B, Davis TN.

J Cell Biol. 1996 Apr;133(1):111-24.

47.
48.
49.

NDC1: a nuclear periphery component required for yeast spindle pole body duplication.

Winey M, Hoyt MA, Chan C, Goetsch L, Botstein D, Byers B.

J Cell Biol. 1993 Aug;122(4):743-51.

50.

Requirement for ESP1 in the nuclear division of Saccharomyces cerevisiae.

McGrew JT, Goetsch L, Byers B, Baum P.

Mol Biol Cell. 1992 Dec;3(12):1443-54.

Supplemental Content

Loading ...
Support Center